Open AccessProspective Randomized Trial of Empiric Therapy with Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High Prevalence of Methicillin-Resistant Staphylococcus aureus
Author(s) -
Mary Jo Cenizal,
Daniel J. Skiest,
Samuel D. Luber,
Roger Bedimo,
Pat Davis,
Patrick J. Fox,
Kathleen Delaney,
R. Doug Hardy
Publication year - 2007
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00206-07
Subject(s) - doxycycline , medicine , sulfamethoxazole , trimethoprim , methicillin resistant staphylococcus aureus , staphylococcus aureus , randomized controlled trial , antibacterial agent , surgery , antibiotics , microbiology and biotechnology , biology , genetics , bacteria
To evaluate empirical therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistantStaphylococcus aureus , a randomized, prospective, open-label investigation was performed. The overall clinical failure rate was 9%, with all failures occurring in the trimethoprim-sulfamethoxazole group. However, there was no significant difference between the clinical failure rate of empirical trimethoprim-sulfamethoxazole therapy and that of doxycycline therapy.